Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Brentuximab Vedotin in Untreated Elderly or Unfit Hodgkin Lymphoma
NCT02758717Phase 2Active, not recruiting
- Sponsor
- Academic and Community Cancer Research United
- Start
- May 2016
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, brentuximab vedotin in Hodgkin lymphoma (HL), sponsored by Academic and Community Cancer Research United. Started May 2016; status: active, not recruiting.
02
Drugs
nivolumabbrentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02758717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02758717.